TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05954598

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: probiotic
Description: This study was designed as a randomized double-blind controlled study. The enrolled subjects were randomized into two groups: intervention group and waiting intervention group. The intervention group received 12 weeks of probiotic intervention from the start of the study, and the waiting group received 12 weeks of placebo intervention from the start of the study. At the start of the study, both groups received 12 weeks of probiotic intervention.
Study: NCT05468528

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: catheter radiofrequency ablation(individualized stepwise linear without pulmonary vein isolation)
Description: individualized stepwise linear ablation without pulmonary vein isolation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: catheter radiofrequency ablation(PVI)
Description: pulmonary vein isolation
Study: NCT04595019

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic Body Radiotherapy. Ultrahypofractionated radiotherapy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT
Description: Stereotactic Body Radiotherapy. Ultrahypofractionated radiotherapy.
Study: NCT05165043

Intervention type: PROCEDURE
Intervention: position change
Description: The patients who conducted position change due to massive EGVB resulting in poor visualization in the stomach were included,patients changed from the left lateral position to the right lateral position.
Study: NCT05996744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeldesivir
Description: Tablet administered orally with or without food
Study: NCT05954598

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic
Description: This study was designed as a randomized double-blind controlled study. The enrolled subjects were randomized into two groups: intervention group and waiting intervention group. The intervention group received 12 weeks of probiotic intervention from the start of the study, and the waiting group received 12 weeks of placebo intervention from the start of the study. At the start of the study, both groups received 12 weeks of probiotic intervention.
Study: NCT05856864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab Injection
Description: Cadonilimab Injection, 10mg/kg, intravenous drip ,q2w,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab Injection
Description: Ramucirumab Injection，8mg/kg, intravenous drip ,q2w,
Study: NCT04563364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interdisciplinary hospital-home intervention
Description: The intervention will start in NICU and to be continued at home with the support of ICT. The NICU intervention will have theoretical and practical components, the theoretical one will be about motor development in premature infants, and practical one will have strategies for motor early intervention, it will be demonstrated with pediatric simulator and parents should be demonstrate it with a infant: 1Sensorial motor stimulation, visual and auditory follow-6up; Tactile integration 3Extension muscle activation 4Middle line integration 5Alignment reaction stimulation in prone position 6Flexor muscle activation with transition to lateral position 7Flexor muscle activation with transition to sitting position 8Facilitation of reciprocal flexion and extension lower limbs. All parents will receive a motor sensorial kit that will include roller, visual tags, blankets and rattles, it will be for apply the strategies for motor early intervention, and will be supported by ICT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Convencional treatment
Description: Control group will receive a conventional treatment given by the institutions
Study: NCT04984408

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell)
Description: * The Inactivated SARS-CoV-2 vaccine (Vero cell)- BBIBP-CorV manufactured by Beijing Institute of Biological Products (BIBP), China National Biotec Group (CNBG), Sinopharm, Beijing, People's Republic of China~* Dose formulation: A liquid formulation containing 4μg total protein with aluminum hydroxide adjuvant (0·45 mg/mL) per 0·5 mL (2-dose schedule followed by a booster dose).~* Mode of Administration: Intramuscular~* Storage Conditions: 2 to 8 degree Celsius

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell)
Description: * The Inactivated SARS-CoV-2 vaccine (Vero cell)- BBIBP-CorV manufactured by Beijing Institute of Biological Products (BIBP), China National Biotec Group (CNBG), Sinopharm, Beijing, People's Republic of China~* Dose formulation: A liquid formulation containing 4μg total protein with aluminum hydroxide adjuvant (0·45 mg/mL) per 0·5 mL (2-dose schedule followed by a booster dose).~* Mode of Administration: Intramuscular~* Storage Conditions: 2 to 8 degree Celsius

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: influenza season quadrivalent Influenza Vaccine (Flu Quadrivalent)
Description: * The southern hemisphere for the 2021 influenza season quadrivalent Influenza Vaccine (Flu Quadrivalent)~* Dose formulation: Purified Inactivated Influenza Virus Antigen H1N1, H3N2, Yamagata and Victoria (single dose, 0.5ml for adults)~* Mode of Administration: Intramuscular~* Storage Conditions: 2 to 8 degree Celsius

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: influenza season quadrivalent Influenza Vaccine (Flu Quadrivalent)
Description: * The southern hemisphere for the 2021 influenza season quadrivalent Influenza Vaccine (Flu Quadrivalent)~* Dose formulation: Purified Inactivated Influenza Virus Antigen H1N1, H3N2, Yamagata and Victoria (single dose, 0.5ml for adults)~* Mode of Administration: Intramuscular~* Storage Conditions: 2 to 8 degree Celsius
Study: NCT04767906

Intervention type: DRUG
Group type: OTHER
Intervention: Cabozantinib
Description: The medication is taken once a day for 336 days (max.). The start dose is 60mg and can be reduced according to the physicians decision. 40mg and 20mg are also available.
Study: NCT06533137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neutral ginger-flavored drink described as energizing, hypoglycemic, caffeine-based drink
Description: It is a neutral ginger-flavored drink with no energizing properties, although it was presented as particularly energizing, hypoglycemic, caffeine-based, and designed to reduce fatigue and improve performance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neutral ginger-flavored drink
Description: A neutral ginger flavoured drink described as an energizing, hypoglycemic, caffeine-based drink, which is designed to reduce fatigue and improve performance.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Neutral ginger-flavored drink
Description: A neutral ginger-flavored beverage bescribed as a mineral salt-based drink
Study: NCT03716726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WE CARE SDoH Screening Survey
Description: The survey will be given at all visits by the front desk staff to all parents of SCA patients. It consists of 12 questions designed to: (1) briefly identify 6 unmet material needs (e.g., childcare, employment, food security, household heat, housing inadequate education) by self-report and (2) using a family-centered approach, determine whether parents would like assistance with each problem Parents wanting help will receive a resource referral. Clinical team members will be trained to review the WE CARE SDoH survey at visits and to provide community resource information sheets to parents with needs. Completed surveys will be scanned into the EHR

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Resource Book
Description: The Family Resource book will contain one-page information sheets listing community resources (e.g., food pantries) and their contact information (i.e. telephone number) for each specific material need (e.g., food insecurity). Information sheets will be specific to each site and written at, or below, the 8th grade level. For parents with an identified need, providers will be instructed to give an information sheet. The book will contain six separate tabs, one for each unmet need, and will contain multiple copies of the information sheets. The Family Resource Book will be made available in each exam room. The investigators will work with each practice to create a Family Resource Book prior to study initiation.
Study: NCT04722835

Intervention type: PROCEDURE
Intervention: Bronchoscopy with Bronchoalveolar Lavage (BAL)
Description: 1. Bronchoscopy w/ (BAL): The bronchoscope will be introduced through mouth and directed into the right middle lobe bronchus for bronchial lavage. The BAL will be performed with two 60-mL aliquots (total of 120 ml) of saline in each of medial and lateral segments of Right Middle Lobe (RML) (total 240 ml lavage).~2. Albuterol Administration: The subjects will inhale 2 puffs of respiratory medication albuterol, then repeat the breathing test.~3. Peak Flow Measurement: Subjects will breathe in fully then out forcefully into the handheld device.~4. Pulmonary Function Test w/ Spirometry: will be used for determination of COPD and its severity. The PFT measures breathing capacity and lung function with different types of breathing maneuvers including flow-volume curve, single breath CO diffusing capacity, and total lung capacity.~5. Blood draw~6. Medical Health and Symptom Questionnaires~7. Physical Exam by study doctor to determine suitability and safety for participation.
Study: NCT03716726

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Usual outpatient care for pediatric patients with sickle cell anemia will be provided.
Study: NCT06246682

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transcanal Endoscopic removal of atticoantral cholesteatoma
Description: removal of the cholesteatoma presented in the atticoantral region by otoendoscope
Study: NCT06009614

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Radicle GI Health Placebo Control Form 1
Description: Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Radicle GI Health Active Study Product 1.1 Usage
Description: Participants will use their Radicle GI Health Active Study Product 1.1 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Radicle GI Health Placebo Control Form 2
Description: Participants will use their Radicle GI Health Placebo Control Form 2 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Radicle GI Health Active Study Product 2.1 Usage
Description: Participants will use their Radicle GI Health Active Study Product 2.1 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Radicle GI Health Active Study Product 2.2 Usage
Description: Participants will use their Radicle GI Health Active Study Product 2.2 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Radicle GI Health Placebo Control Form 3
Description: Participants will use their Radicle GI Health Placebo Control Form 3 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Radicle GI Health Active Study Product 3.1 Usage
Description: Participants will use their Radicle GI Health Active Study Product 3.1 as directed for a period of 6 weeks.
Study: NCT04909567

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimisation
Description: Defined optimisation
Study: NCT05838417

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REDS survey
Description: R - Reactance, E - self-Exemption, D - Disbelief, S - Source derogation
Study: NCT05936151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retatrutide
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT06489028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allo-APZ2-CVU
Description: Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06496178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Petosemtamab
Description: MCLA-158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator's Choice
Description: Cetuximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator's Choice
Description: Methotrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator's Choice
Description: Docetaxel
Study: NCT05704530

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Retrospective collection of leftover tissue from standard of care biopsies or resection specimens and prospective collection of additional blood samples for study-specific analyses at specific timepoints, at the same time as routine labs are foreseen. No additional venipunctures are expected.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Retrospective collection of leftover tissue from standard of care biopsies or resection specimens and prospective collection of additional blood samples for study-specific analyses at specific timepoints, at the same time as routine labs are foreseen. No additional venipunctures are expected.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Retrospective collection of leftover tissue from standard of care biopsies or resection specimens and prospective collection of additional blood samples for study-specific analyses at specific timepoints, at the same time as routine labs are foreseen. No additional venipunctures are expected.
Study: NCT05337449

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: silver diamine fluoride
Description: silver diamine fluoride is a colorless with high PH topical fluoride solution of 38% weight/volume use for arresting early childhood caries

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: silver diamine fluoride
Description: silver diamine fluoride is a colorless with high PH topical fluoride solution of 38% weight/volume use for arresting early childhood caries

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional composite resin restoration
Description: Dental composite resins are dental cement made of synthetic resins which were insoluble, of good tooth-like appearance, insensitive to dehydration, and easy to manipulate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional composite resin restoration
Description: Dental composite resins are dental cement made of synthetic resins which were insoluble, of good tooth-like appearance, insensitive to dehydration, and easy to manipulate.
Study: NCT06417684

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: 25 mg prescribed to be taken once daily for 90 days each evening.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: 25 mg prescribed to be taken once daily for 90 days each evening.
Study: NCT06282380

Intervention type: DEVICE
Group type: OTHER
Intervention: FibriCheck Mobile Application
Description: PPG measurement with reference diagnosis
Study: NCT06082778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fermented food intake above habitual level
Description: Participants increase their habitual intake of fermented foods by three portions per day, compared to their habitual intake level at baseline.
Study: NCT04278261

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focal therapy(high-frequency irreversible electroporation)
Description: High-frequency irreversible electroporation will be performed via the perineum with the guidance of ultrasound under general anaesthesia to the patient with localized prostate cancer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic radical prostatectomy
Description: Laparoscopic radical prostatectomy
Study: NCT05623735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization Group While Lying Prone
Description: 1. Sliding movements in all directions at 30 - 60 degree angles will be made in the form of mobilizations of 45 seconds with instruments.~2. Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~3. Starting with an angle of 60 degrees on the area to be treated, the movement of shifting towards an angle of 30 degrees will be made in all directions for 30 seconds.~4. The tissue will be mobilized for 30 consecutive seconds, starting from just caudal to your waist and drawing the letter J towards the cranial.~5. Sliding movements in all directions at 30 - 60 degree angles will be made with instruments in the form of mobilizations for 45 seconds.~6. Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~7. 30 - 60 degree swipe movement shorter brushing style small movements will be done for 30 seconds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization Group Combined with Functional Movement
Description: 1. Sliding movements in all directions at 30 - 60 degree angles will be made in the form of mobilizations of 45 seconds with instruments.~2. Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~3. Starting with an angle of 60 degrees on the area to be treated, the movement of shifting towards an angle of 30 degrees will be made in all directions for 30 seconds.~4. The tissue will be mobilized for 30 consecutive seconds, starting from just caudal to your waist and drawing the letter J towards the cranial.~5. Sliding movements in all directions at 30 - 60 degree angles will be made with instruments in the form of mobilizations for 45 seconds.~6. Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~7. 30 - 60 degree swipe movement shorter brushing style small movements will be done for 30 seconds.
Study: NCT05793086

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Using shear wave elastography and gray scale analysis of ultrasound.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Using shear wave elastography and gray scale analysis of ultrasound.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Using shear wave elastography and gray scale analysis of ultrasound.

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrical impedance myography
Description: Measurement of localized bioimpedance of muscle

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrical impedance myography
Description: Measurement of localized bioimpedance of muscle

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrical impedance myography
Description: Measurement of localized bioimpedance of muscle

Intervention type: DIAGNOSTIC_TEST
Intervention: Excitability testing
Description: Electrical studies of myofiber excitability

Intervention type: DIAGNOSTIC_TEST
Intervention: Excitability testing
Description: Electrical studies of myofiber excitability

Intervention type: DIAGNOSTIC_TEST
Intervention: Excitability testing
Description: Electrical studies of myofiber excitability
Study: NCT06219343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive vagus nerve stimulation
Description: Patient undergoes non-invasive vagus nerve stimulation during tachycardia episodes to see if reentry is possible
Study: NCT06527079

Intervention type: OTHER
Intervention: Opioid Tapering Pathway Clinical Decision Support (CDS)
Description: Clinical decision support in the form of an electronic health record (EHR)-integrated, provider facing notification suggesting the provider utilize a clinical care pathway that provides resources and decision support in opioid tapering in line with CDC guidelines.
Study: NCT05085288

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent electrical stimulation system (IES) treatment and turning patient every two hours
Description: The investigators propose to assess whether addition of the IES system and the use of standard of care wound care and wound prevention reduces the morbidity of sacral and ischial pressure injuries by decreasing progression of stage 1 and stage 2 ulcers or facilitates their healing compared to standard wound care in an inpatient critical care population.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Turning population every two hours
Description: The investigators propose to assess whether current standard of care wound care and wound prevention reduces the morbidity of sacral and ischial pressure injuries.
Study: NCT06034197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGT-309
Description: 0.32mg/kg IV of VGT-309 given 12-36 hours before surgery
Study: NCT06510491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Bispecific antibody, via subcutaneous (under the skin) injection per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Bispecific antibody, via subcutaneous (under the skin) injection per protocol.
Study: NCT06245707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone,methylprednisone and cyclophosphamide
Description: In the first month, methylprednisolone 500mg/d was given intravenously for 3 days, and then prednisone 0.5 mg/(kg d) \* for 27 days. Oral cyclophosphamide 2.0 mg/(kg d) \* 30 days in the second month. After that, the first month and the second month plan were repeated twice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: The dosage of rituximab depends on peripheral blood B cells. After the treatment of rituximab, the peripheral blood B cells were in a clear state and then stopped. After monitoring the recovery of B cells, additional doses were given.
Study: NCT04772131

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Desara® One Single Incision Sling
Description: Single incision sling

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Desara® Blue Transobturator Sling
Description: Standard mid-urethral sling
Study: NCT05708378

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rocker board training
Description: Patients will perform 24 sessions (4 times per week over 6 weeks) and effects will be measured before treatment, at 3rd and after 6th week.

Intervention type: OTHER
Group type: OTHER
Intervention: Stable surface training
Description: Patients will perform 24 sessions (4 times per week over 6 weeks) and effects will be measured before treatment, at 3rd and after 6th week.
Study: NCT05652179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: After the induction of general anesthesia and before the start of the surgery,ultrasound-guided stellate ganglion block is performed, injecting 5 ml of 0.375% ropivacaine.